Monday, November 16, 2026

CMS RELEASES "CRUSH" ANTI FRAUD RULE: ZIPPO RE LABS

CMS has released a proposed version of its new anti fraud CRUSH rules.  While the roll-out seemed to be "half DME and half lab industry," the proposed rule hardly mentions the word "laboratory."

Press:

https://www.cms.gov/newsroom/press-releases/cms-crush-proposed-rule-aims-reap-nearly-90-billion-taxpayers-savings-targeting-fraud-across

FAQ:

https://www.cms.gov/newsroom/fact-sheets/comprehensive-regulations-uncover-suspicious-healthcare-crush-proposed-rule-cms-6098-p

Proposal:

https://public-inspection.federalregister.gov/2026-23461.pdf


CMS Releases CRUSH: 545 Pages on Fraud, and Labs Barely Appear

On November 16, 2026, CMS released the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule, CMS-6098-P. The agency says it would save nearly $90 billion over ten years across Medicare, Medicaid/CHIP and the ACA Marketplace. It is a standalone, discretionary program integrity rule rather than an annual payment rule. CMS says it intends to issue a rule like this every year from now on. The Federal Register publishes it November 19, and comments are due January 19, 2027.

The press release goes heavily after DME, hospice and Marketplace brokers. Administrator Oz's quote mentions fake canes and wheelchairs, healthy seniors enrolled in hospice, and consumers signed up for Marketplace plans without their consent. The largest single dollar item is Medicare Advantage RADV reform. CMS would codify no fee-for-service adjuster and extrapolation starting with payment year 2018 audits, which it estimates at about $9 billion per payment year. Other items include mandatory fraud reporting by MA and Part D plans, a new Medicaid audit structure for eligibility, a 60-day overpayment rule for Medicaid fee-for-service, and tighter rules for Marketplace agents and brokers.

Where are the labs?

Much of the recent fraud debate in diagnostics has been about laboratory billing. Readers in that sector might have expected a large lab section. There isn't one. Explicit references to laboratories are sparse and largely incidental. The word "laboratory," for example, appears 3 times.

  • once in a Medicaid list of "disclosing entities" (p. 213)
  • once in a regulatory subject index
  • once as a reassurance that a medical building housing "two laboratories" next to other practices is not, in itself, a sign of fraud (p. 199)

Genetic testing comes up only once. It appears in a DOJ case summary in the DMEPOS section (p. 184): a Texas defendant sentenced in March 2026 for a $61.5 million scheme. An offshore call center sold Medicare beneficiaries braces, foot baths and genetic tests they did not need. There is no lab provision, no CLIA hook, and nothing about MolDX, PLA codes or test-specific edits.

  • The rule does contain several broad enrollment changes that apply to every provider and supplier type, including independent labs.
  • For lab compliance teams, those are the parts to read.

CMS Publishes Template for Uses of SUPER INTELLIGENCE in Medicare, Medicaid

Recall that recently, HHS ordered that HHS, CMS, NIH, FDA, all use "SUPER INTELLIGENCE" rather than artificial intelligence.  My blog.

We've now got a brand new 8 page report on how cMS wants to use SUPER INTELLIGENCE to lower costs while giving better answers and faster care.  And it's getting some press.

Find the 8 page white paper here:

https://www.cms.gov/files/document/clinical-si-roadmap.pdf

Coverage at Becker Health IT here.  At Orange Slices here.

##
AI CORNER

##


CMS’s AI Roadmap: Better Diagnostics, More Physician Capacity—and Lower Costs

CMS has released an eight-page Clinical Super Intelligence Roadmap, laying out an ambitious federal agenda for clinical AI. For readers in radiology, pathology, and genomics, it deserves attention for both its enthusiasm about technology and its pointed message about reimbursement: CMS wants AI to improve care while bringing costs down.

Read the CMS announcement and the eight-page roadmap. The document was posted November 13.

The roadmap’s subtitle is Better Answers, Faster Care, and Lower Costs. Those objectives could apply directly to software that helps a radiologist complete an interpretation, a pathologist sign out a case, or an oncologist understand a complex molecular report. Much of the immediate policy discussion concerns primary care and chronic disease, but the implications for diagnostic medicine are substantial.

The payment message deserves particular attention. On page 7, CMS states:

“Technology should be deflationary to costs.”

FDA Downclassifies Again: IHC for CDx

I posted a blog on September 3, 2026, that FDA had recently downclassified oncology cDx with ISH or FISH from  Class III (PMA) to Class II (e.g. 510k or de novo 510k).  At the time, the news was two weeks old but had gotten very little press.

Now, in November, similar news for a much larger area, IHC, immunohistochemistry.

This should be the auto AI that Google itself gives you: 

https://share.google/aimode/O5TrMaWcf2m8Ki6J1

Here's the FDA reclassification proposal:

https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with

FDA accepts public comment now and will finalize in a year or two.  You have until January 11, 2027.


Pubmed tells us FDA wrote about the topic on June 3, 1998, PMID 10179865.   Here.  63fR30132.

Read about the new publication at Sharon Liang at linked in here.

IHC is hardly cut and dried, see debates about PDL1 staining and about Enhertu in pan cancer here.

###

AI CORNER

###


FDA Proposes Easier Market Entry for Oncology IHC—and a Regulatory Gem from 1998

The proposed move from PMA to 510(k) has a revealing historical precedent.

The 2026 Proposal

On November 12, FDA proposed reclassifying oncology immunohistochemistry (IHC) test systems from Class III to Class II, replacing premarket approval (PMA) with 510(k) clearance and special controls. Comments are due January 11, 2027.

The scope includes companion diagnostics essential to treatment selection, plus certain tests that inform a drug’s benefits or risks without being prerequisites for treatment. FDA proposes a new regulation, 21 CFR 864.1895.

Substantial Evidence Requirements Remain

The proposed controls require analytical and clinical performance evidence, validated scoring thresholds, and reproducibility—including between readers and near clinical decision cutoffs.

Former FDA leader Sharon Liang, in her recent LinkedIn commentary, highlights why this matters for PD-L1: different antibody clones, scoring systems, thresholds, and reader variability complicate reliable treatment selection. Her discussion places IHC within FDA’s broader effort to reclassify higher-risk IVDs.

Using AI at my Desk at Work: A Weekly Agentic Search for AI Report Generation Advances (Radiology or Pathology)

 Each Monday, I used "agentic AI" to run a complex scheduled AI search in Chat GPT.  The topic is new publications related to generating either Radiology or Pathology repors by AI, including news about FDA reviews, etc.  (It also tracks FDA K260303 web page).

##

Here is a cut/paste out of what it delivered to me for November 16, 2026.  Note that at bottom, I also gave it a link to news from Cognita, which it then discusses.

##

Weekly AI Diagnostic Report-Generation Watch

Monday, November 16, 2026

The most consequential new finding is from AMP 2026: University of Michigan investigators presented an AI system that generates evidence-supported molecular pathology reports, while Memorial Sloan Kettering researchers demonstrated AI-assisted selection of molecular tests. Together, these developments approach the integrated laboratory workflow we've been tracking.

Thursday, November 12, 2026

Two Authors, Two Books on Digital Pathology

 This week, I ran across two authors on Linked In who have each written a book that introduces the world of digital pathology.

The first author is Dr. Aleks Zuraw.  Her book is a take-home associated with a webinar she is giving this week.   "Digital Pathology 101, 2nd Edition."  Find registration here:

https://lnkd.in/p/grdGQian

and

https://lnkd.in/p/gVByAMuS

####

The second author is Dr. Luis Cano.  His book is a highlighted link on his Linked In homepage  find it here:

https://payhip.com/b/wldfe 

####

Chat GPT 6 reviews both books together.

####

I recently discovered two authors on LinkedIn whose introductory books offer complementary perspectives on digital pathology: Luis Cano’s Getting Started with Digital Pathology and Aleksandra Zuraw’s Digital Pathology 101, now in its second edition. Both help readers understand how scanned tissue images can support diagnosis, research, and computational analysis, but their emphasis differs substantially.

Cano’s concise guide is particularly effective at introducing quantitative tissue analysis, including cell counting, biomarker scoring, segmentation, and spatial relationships within tumors. His practical advice encourages newcomers to begin with accessible software, public datasets, and manageable projects.

Zuraw provides a broader introduction to the infrastructure and organizational work required for implementation. Her strongest sections address validation, workflow integration, ongoing performance monitoring, and the distance between developing an algorithm and deploying it reliably. Her veterinary and pharmaceutical background also supports distinctive coverage of toxicologic pathology and regulated drug development.

Neither book provides a complete treatment of clinical utility, reimbursement, procurement, or investment analysis. Nevertheless, both are valuable starting points. 

Pathologists, translational researchers, and industry professionals who must connect scientific possibilities with practical adoption should consider reading both: Cano for an accessible entry into image analysis, followed by Zuraw for a deeper understanding of implementation and operational responsibilities.

FIND FULL REVIEW:

https://drive.google.com/file/d/1Wisq0R2DxSGfh3o1--_7nCj3YBht3T4q/view?usp=sharing 





Brief Blog: How CMS Updates Products Covered Under NCDs

A brief update on how CMS covers products that are covered by definition, under an NCD.  

The example here is NCD 90.2, Uses of NGS in Cancer.   FDA cleared-or-approved companion diagnostics are covered by this NCD for on-label uses.   Often, this means PMA CDx approval for one or more indications (gene-drug), and a secondary FDA label which is for profiling mutations in tumor genes in solid tumors, for the use of the physician via guidelines.

So on October 23, 2026, CMS released CR 14653, T 14022, Revisions to NCDs.  It's released on October 23, effective April 1 2027 (the new quarter) ("unless otherwise stated"), implementation date April 5, 2027.

https://www.cms.gov/files/document/r14022otn.pdf

On page 3 we read that per task order 14653.1, the PGDX Elio Tissue Complete CDx is covered effective back on the FDA approval date July 30, 2026.  Use CPT 81459 until a PLA is established.  

The last page of the CR includes a link to a cloud zip file for Excel version.


Labcorp web page, 505 total genes and signatues TMB, MSI.

https://www.labcorp.com/oncology/providers/testing-solutions/kitted-solutions/pgdx-elio-tissue-complete-cdx

Product brochure 4pp

https://www.labcorp.com/content/dam/labcorp/files/oncology-launch/etc-cdx-oncology-brochure-2026.pdf


###

I believe that a version of PGDx elio had FDA 510k clearance (not approval) for tumor profiling, whereas this FDA revision is a PMA for a BRAF gene in melanoma PLUS tumor profiling use.  Here, here.

###

It's clear to me that program instructions defined effective date as the coverage date, and implementation date as the LATEST or LAST date to "implement" that coverage.

https://www.discoveriesinhealthpolicy.com/2026/02/this-may-save-your-reimbursement-nerd.html

However, MACs may say CMS forbids them to cover for that effective date and later, UNTIL the "implementation date" has passed.

###

81459 pays $2989 (no PAMA change) and represents,

Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; dna analysis or combined dna and rna analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


Wednesday, November 11, 2026

PAMA: The Secret Data Views that CMS Never Displays (for GSP Genomic Sequencing Procedures)

Medicare genomic sequencing pricing under PAMA is based on anywhere from 200 to 275,000 claims for the "GSP" service type.   For Exome and Genome, a large body of claims were paid at about half the Medicare CLFS rate.

Note that none of this data is Medicare data; it's private payer data...the behavior of private payers

###

Goodbye to a myth?

Are CMS CLFS prices a benchmark that strongly drive the market?   Well, the data shows that for some  codes (from 81408 to 81425) the actual market prices can be skewed or centered quite a distance from the CLFS benchmark at the time.

###

What's Up?

Medicare's public raw data files for PAMA 2026 provide interesting data views.  Here, I reveal some more, using simple commands and Chat GPT 6.

Case Study: GeneDx (ticker WGS)

The information is relevant. Over the past year, GeneDx has been battling reimbursement issues, with share price varying in that time from around $33 to around $170.  On one day in May, the share price dropped 50%.   

PAMA Prices Trend Down for Exome, Genome

Not helping is the downward trend in the latest PAMA data for genomic procedures, including 81415 exome and 81425 genome.   Here's some data; I include the $2000 (CLFS) rare gene code 81408.

In each case below, the current CMS CLFS price is in the fourth column.  But a lot of the reported payments are cheaper: most of the claims for 81415 (exome, middle row) and 81425 (genome, bottom row) are in the second and third columns.  Those are claims at $1400-2800 [second column] and $2800-4200 [third column.] 

Note that exome, but not genome, has a significant bump to-the-right (blue bar in column 6).  We showed earlier that such behavior, high-paying plans, can really drive free cash flow and profit.  


Star - CLFS price

The skew to the left is even more prominent for 81408, where many payments populate the far left bar ($0-550, while CMS price, $2000).

So if my market depended on the price of Genome being $5000 or nearby, and the largest bucket was column 2, $1400-2800... eeek.

##

Also in the 814nn series, GSP or Genomic Sequencing Procedures, CMS let us count how many services or claims were reported for about 36 GSP codes.   Here is a sample screen shot:


Here's the full table:


Here's the Tier 2 claims, 81400 to 81408 as a bar chart.





Tuesday, November 10, 2026

Devil in the Details; Understanding GeneDx's Earning Shocks via Reimbursement

 

GeneDx Earnings Calls Show Why Reimbursement Determines the Economics of Genomic Testing

GeneDx’s May earnings shock (down 50%) exposed the financial consequences of a rapid shift toward genome sequencing. Its August and November calls trace the response: manage test mix, expand coverage, and improve collections. The latest results show progress, alongside a practical tradeoff between frictionless ordering and the documentation needed to secure payment.

ChatGPT 6 (Los Angeles, November 10, 2026). GeneDx’s November earnings discussion offers a detailed account of a problem that extends across advanced diagnostics: clinical demand can grow faster than the machinery that converts testing into payment. A laboratory can perform more tests, deliver valuable answers, and still collect less revenue per case than its business plan anticipated.

GenomeWeb captured the latest development in its November 10 headline, “GeneDx Shares Drop as Firm Starts Prioritizing Reimbursement Over Testing Volume.” The company is collecting more documentation before genome testing begins, accepting some delays and lower near-term volume expectations in exchange for a better prospect of reimbursement.

The stock reaction deserves perspective. Shares fell from approximately $65.72 to $54.83 on November 10, about 16.6%, while the five-day chart shows a decline from roughly $69 to $55. But the shares had also traded near $100 only a few months earlier, and their 52-week range was approximately $32 to $171. The latest decline sits within a much larger history of volatility.

The more informative story begins in May. That quarter exposed the economic problem; August described the repair strategy; November showed both progress and the friction involved in carrying it out.

May exposed the consequences of the genome transition

The striking early-May discontinuity in GeneDx’s stock chart followed its May 4 first-quarter report. On May 5, shares fell approximately 49%, closing at $34.51. The company reduced annual revenue guidance from $540–555 million to $475–490 million, a $65 million reduction at the midpoint. investors.com

The May earnings call explained that the shift toward genome had depressed blended average reimbursement. Management attributed $36 million of the annual revenue revision to reimbursement effects associated with product mix, $11 million to lower volume contributions from expansion markets, and $18 million to noncore businesses.

An important qualification accompanied that explanation. Management said contracted prices and collection rates within the respective products and channels had not materially changed in Q1. The immediate surprise was the composition of the business: a greater share of testing was moving into services with less favorable realized economics. The Motley Fool

This distinction matters. A laboratory does not need to experience an explicit payer price cut for its average revenue per test to fall. A change in what clinicians order—and the settings and payer populations in which they order it—can produce that result.

August laid out the repair strategy

By the August 3 second-quarter earnings call, GeneDx was describing a coordinated effort to improve reimbursement. Management emphasized test mix, coverage expansion, payer-specific workflows, and technology investment.

The underlying economics challenged an intuitive assumption that a broader assay should generate more revenue. GeneDx reported that genome’s contracted rates were lower than exome’s, while genome cost nearly twice as much to produce, largely because of reagents.

Collections added another constraint. Only about 32% of outpatient genome claims were being paid, versus 43% a year earlier. Management described the earlier acceptance of volume ahead of coverage as a market-development investment.

The company began moderating the transition. Genome’s share of outpatient insurance-based testing fell from nearly 40% in Q1 to 32% in Q2, with more emphasis on exome and reflex offerings. Genome remained the long-term destination, but the company was adapting the pace of adoption to the economics of delivering it. The Motley Fool

GeneDx reported Q2 revenue of $114.4 million, adjusted gross margin of 70%, and adjusted net income of $0.4 million. The improvement established a baseline for the next phase of the reimbursement work. ir.genedx.com

November made the operational tradeoff explicit

The November 9 third-quarter earnings call described what happens when a laboratory begins enforcing more of the payer’s documentation requirements before it performs the test.

GeneDx aligned genome workflows to obtain additional information from clinicians before laboratory testing started. This can improve the likelihood that the eventual claim satisfies the payer’s requirements. It can also extend the interval between receipt of an order and the start of testing.

Management reported cancellations, downgrades, and delayed starts. Accessions grew 28% year over year, while completed exome and genome result volume grew 25%. The company lowered its full-year expectations for exome and genome volume growth from at least 30% to at least 28%, and revenue growth for those services from at least 20% to at least 17%. GeneDx, LLC

Those changes illustrate why revenue cycle management is a clinical workflow issue as well as a billing function. The information needed for payment often originates in the ordering clinician’s office. If it is missing, the laboratory must obtain it, proceed with reimbursement uncertainty, or alter the testing pathway.

A process that is easy to order can generate strong demand while leaving substantial work unresolved downstream. Moving that work earlier makes the obstacle visible to clinicians and patients before testing proceeds.

What the denial analysis revealed

President Mark Gardner supplied one of the most consequential details of the November call. GeneDx’s analysis classified 62% of exome and genome denials as administrative or procedural. The remaining 38% involved disputes over clinical necessity or patients outside payer coverage policies.

The distinction identifies two different kinds of work. Administrative denials may respond to better documentation, authorization procedures, claim preparation, and follow-up. Coverage and medical-necessity problems may require new evidence, policy changes, or a different way of financing access.

The percentages describe the composition of denials. They do not mean that 62% of all tests were denied, or that correcting administrative processes will automatically recover 62% of lost revenue. Management’s assessment identifies the principal area of opportunity; the financial outcome still depends on execution.

For market access teams, the finding is particularly useful. Obtaining a favorable policy is only one part of commercialization. The laboratory must also demonstrate that a particular patient meets that policy’s requirements and present the claim in the form the payer will accept.

The financial results show progress with limits

The quarter’s results indicate improvement, although the year-over-year comparisons remain more difficult than the sequential ones.

MeasureQ2 2026Q3 2026
Total revenue$114 million$123 million
Exome and genome revenue$100 million$110 million
Exome and genome tests resulted30,78532,134
Blended average reimbursement per test$3,258$3,436
Genome share of outpatient insurance volume32%26%
Outpatient genome claims paid32%36%
Adjusted gross margin70%72%
Adjusted net income$0.4 million$8.6 million

Sources: GeneDx quarterly disclosures and earnings calls; November 10 GenomeWeb reporting. www.fool.com

Blended reimbursement rose approximately 5% sequentially, helped by better genome collections and the shift toward exome. However, it remained below the approximately $3,800 reported in Q3 2025. Exome and genome volume increased 25% year over year, while revenue from those services increased 12%.

The product mix is important to interpreting the improvement. A higher blended reimbursement figure can reflect better collections, a larger share of better-reimbursed tests, or both. It should not automatically be read as an increase in payer prices.

Nor should the company’s losses be interpreted as evidence that every genome test loses money. GeneDx reported a Q3 GAAP net loss of $12.3 million while generating positive adjusted net income. Company profitability, product gross margins, and the economics of an individual claim are different measures.

Coverage must become operational before it becomes cash

The latest call also distinguished formal coverage from payment in practice. Management reported that 82% of outpatient genome volume was submitted to payers with positive coverage policies, up from 67% in Q2. Yet the genome collection rate was 36%; exome’s was approximately 32%.

These measures have different definitions and should not be subtracted to calculate a denial rate. Together, however, they show why a coverage announcement does not immediately resolve reimbursement.

Management attributed part of the genome collection improvement to plans following Carelon’s coverage policy. Medi-Cal implementation remained more difficult, with a larger benefit expected in 2027. Payers must translate coverage decisions into operating procedures, while laboratories must satisfy the patient-specific requirements. www.fool.com

GeneDx is investing in technology and artificial intelligence to make these processes easier to navigate. Such systems may help obtain and organize information, but they cannot by themselves create coverage for an excluded patient or establish clinical utility where a payer remains unconvinced.

The company’s appointment of Nicole Maassen as chief patient access officer, overseeing market access and government affairs, places these responsibilities prominently within its leadership structure.

PAMA adds a second reimbursement challenge

The collection problem is occurring alongside a prospective reduction in the reference prices used by many payer contracts.

The October 12 analysis of exome and genome pricing reported CMS’s preliminary PAMA median targets of $3,680.60 for exome, CPT 81415, and $3,018.72 for genome, CPT 81425. Genome’s ultimate target is approximately 18% below exome’s.

The reduction limits delay the crossover in actual Medicare payment:

Rate or projectionExome 81415Genome 81425
2026 CLFS rate$4,780$5,031
Preliminary capped 2027 payment$4,063$4,276
Projected 2028 payment$3,680$3,635
Preliminary ultimate median target$3,680$3,018

The 2028 figures are projections assuming unchanged preliminary medians and reduction limits, rather than separately announced CMS rates. The reference-price inversion begins in 2028 under those assumptions. www.discoveriesinhealthpolicy.com

The business implication reaches beyond direct Medicare claims. On the November call, CFO Kevin Feeley said approximately 45% of company revenue was exposed to PAMA through CLFS-linked contracts. Management anticipated a mid-single-digit headwind to total revenue in 2027, while expecting collection improvements to offset or exceed it. www.fool.com

Those are separate forces. Improving the percentage of tests paid can raise revenue even while the payment benchmark declines. Conversely, growing test volume does not guarantee revenue growth if collections weaken or the reference rate falls.

The next stage is a test of execution

GeneDx’s three earnings discussions describe an evolving response to the same economic challenge. May revealed the consequences of a faster genome transition. August established the repair strategy. November demonstrated an initial improvement in reimbursement and margins, while exposing the delays and ordering friction that the strategy can create.

The company retained its full-year revenue range of $475–490 million and raised its adjusted net income outlook to approximately $12 million, even as it reduced exome and genome growth expectations. That combination explains the tension facing investors: improving economics per test can coexist with a more cautious near-term growth outlook. GeneDx, LLC

The next evidence will come from sustained collections, the time required to move orders into testing, and the extent to which reimbursement improvements persist as genome utilization rises again. For the wider diagnostics sector, GeneDx provides a concrete example of how clinical adoption, coverage policy, laboratory operations, and payment must advance together for scientific capability to become a durable business.

##

Note:  CMS PAMA data tell us nothing about how much GeneDx gets paid; that's hidden.  But PAMA data does show that in 2025, large numbers of commercial claims for exome 81415 and genome 81425 were getting paid at around half the CLFS price.  Here.


Sunday, November 8, 2026

Chris Klomp: #2 at HHS, Update on his Views and Priorities for CMS

HEADER.  Chris Klomp is about to become the official #2 at HHS - the Deputy Secretary.  How does Klomp think Medicare should pay for innovation? His recent WSJ interview and two Senate hearings offer revealing answers: reward outcomes, make clinical AI reduce costs, and align FDA and CMS evidence expectations earlier. But the details matter: RAPID excludes laboratory tests, and senators challenged AI-assisted prior authorization. Our deep-dive AI review examines and connects all three appearances to explain an increasingly influential HHS official’s priorities—and what they could mean for diagnostics, biotechnology, and reimbursement.

###
AI CORNER
###

In March, this blog featured several articles about Chris Klomp, a senior CMS policymaker who was being moved to a #2 position under RFK Jr at HHS.  A Senate committee recently moved his nomination for Deputy Secretary forward.

What's new for him?  WSJ just published a 25-minute interview between Klomp and Liz Whyte.  Find it here.   We cover that first.  Then, in a second section, we provide highlights from his Senate appearances in September.

Across all three appearances, Klomp returns to several consistent themes:

  • Reward outcomes rather than activity. The hearings emphasize shared savings and appropriate preventive spending; the WSJ interview extends this argument to clinical AI and explicitly cites ACCESS.
  • Accelerate innovation while preserving standards. September 15 highlights FDA–CMS evidence alignment; September 16 emphasizes inspections and development timelines; WSJ broadens this into faster trials and biotechnology competitiveness.
  • Lower drug costs without weakening American biotechnology. He repeatedly presents these as simultaneous obligations.
  • Modernize government technology. The hearings focus on aging Medicare systems; WSJ emphasizes interoperable data as essential infrastructure for clinical AI.
  • Manage through trust, competence and accountability. These leadership principles recur almost verbatim.

The strongest continuity is his belief that better incentives and better execution can improve access while restraining costs. The WSJ interview develops that philosophy more expansively; the hearings expose the difficult implementation questions.

###

Saturday, November 7, 2026

AI Guest Faculty: Lessons from 1870s for Growth of Genomics Today

 What can the rise of Germany’s synthetic-dye industry in the 1800s teach us about American genomics today?

Johann Peter Murmann’s fascinating historical research, followed by a 2016 computer simulation, offers an unexpected starting point.

My new white paper explores how scientific talent, capital markets, and Medicare reimbursement shape industrial winners and losers. One intriguing question: Would genomics have evolved differently if Medicare coverage had been fragmented among 20 independent regional payers?

A historical comparison—and a proposed AI-assisted experiment.

###

###

Executive Summary

Why do some genomics companies become industry leaders while others, sometimes equally innovative, struggle or disappear? The answer may lie as much in institutions and financing as in scientific discovery.

This white paper draws an unexpected historical comparison with the nineteenth-century German synthetic-dye industry. In his 2003 book, Johann Peter Murmann examined how universities, scientific talent, patent laws, and industrial competition helped Germany achieve global dominance. In 2016, Murmann and Thomas Brenner used computer simulations to test these historical explanations, finding that universities' responsiveness to industry's demand for chemists was particularly consequential.

The paper proposes applying a similar approach to the evolution of American genomics, with special attention to Medicare reimbursement and MolDX.

One largely overlooked institutional feature deserves scrutiny: a centralized laboratory can receive traditional Medicare reimbursement for testing beneficiaries nationwide through its own Medicare contractor. What if Medicare had instead been divided among dozens of independent regional payers, each making separate coverage decisions?

Such fragmentation might have profoundly altered the industry's financing, growth, and competitive landscape.

The paper outlines an AI-assisted research program combining company histories, reimbursement decisions, financial data, and computational simulations to investigate these possibilities.

The objective is not merely to explain which companies succeeded, but to understand how America's institutional environment helped shape their success.

###

DOWNLOAD THE 10p PDF WHITE PAPER... HERE.



Friday, November 6, 2026

Three Companies: Investor Calls for Tempus AI, Caris, and Natera, Quarter to Quarter

Tempus, Caris, and Natera see enormous opportunity in genomics—but reimbursement determines the pace. Our new AI-generated white paper compares November earnings calls with prior-quarter expectations, examining MolDX coverage, payer pricing, clinical evidence, and promises still awaiting payment.

Here's a summary:

  • Tempus AI, Caris, and Natera report strong demand for genomic testing, but reimbursement determines how quickly new products become sustainable businesses. Comparing November earnings calls with the prior quarter reveals distinct strategies. 
    • Tempus anticipates substantial oncology pricing gains while pacing MRD expansion around coverage.
    • Caris expects higher liquid-biopsy reimbursement to help finance new monitoring and detection products.
    • Natera is converting clinical evidence into broader coverage, including a new MolDX indication for liver cancer surveillance. Several earlier expectations remain unresolved, particularly payment for emerging applications and Japanese commercialization.
      • [Steve Chapman steps down as CEO - here.] 
  • Across the companies, the key distinction is between technical performance, clinical utility, coverage, and actual collections. Competitive advantage increasingly depends on generating persuasive evidence and financing the long interval before reliable payment.
Find the 15-page report in the cloud  HERE.


x
x






Why a Strong Diagnostic Test May Add Little New Information

 #

Why a Strong Diagnostic Test May Add Little "New" Information

[Chat GPT 6]

My colleague Luis Cano recently posted a useful example of a question that diagnostic developers should ask much earlier: What does the new technology add to what we already know?

His post described a pancreatic neuroendocrine tumor preprint involving 1,438 patients and approximately 30,000 histology images. An AI model extracted prognostic information from routine H&E slides.  

Yet, as Cano reported, a model using established clinicopathologic information achieved a C-index of 0.875; adding the AI increased it to 0.883. [Sivasubramanian]

The AI could predict recurrence. The clinical information could already predict recurrence very well. Those findings can coexist.

My comment on his post drew on a lesson I remember from MBA statistics. Given an outcome and ten candidate variables, variables A, B, and C might predict the outcome extremely well. Then variables D, E, and F might do almost as well. That does not mean we have discovered two separate reservoirs of predictive power that we can simply add together. We may have found two ways of measuring much of the same thing.

For molecular diagnostics, digital pathology, and AI, this distinction can separate an impressive publication from a compelling case for clinical adoption.

The arithmetic works but the attribution changes

We expect addition to be commutative: 3 + 5  =  5 + 3. It is tempting to assume that combining predictors works the same way.

An important qualification makes the lesson precise. Ordinary correlation is symmetric: the correlation of X with Y equals the correlation of Y with X. And if we fit the same ordinary regression model to the same data with the same predictors, simply rearranging the columns does not change its final predictions.

  • What depends on order, is the incremental credit we assign to each source of information.

“How well does this test predict recurrence?” and “How much does this test improve prediction after we use the pathology report?” are different questions.

The first measures performance in isolation. The second measures added value against an existing baseline. A test can perform very well on the first and make only a modest contribution on the second.

Here, “clinical first” means choosing the clinical model as the benchmark. 

Thursday, November 5, 2026

The Genomics Consulting Book Guide to CLAUDE

If this looks familiar, I posted at Linked In  about November 1, but not here at the DIHP blog.

They Infest Linked In

Lately, every day Linked In has been offered me "McKinsey Guide to CLAUDE," "Consultant's Guide to CLAUDE."  Usually the exciting-sounding offers dead end at a registration page and sign in with your email.



Steve Jobs Got His Best Ideas Walking, Too

Walking home from lunch with some consultant colleagues, it occurred to me that my own Claude account could probably write me a guide to strategy consulting in ten minutes. It did. And honestly, it’s pretty good.

As I read, I kept thinking: “I can use THIS to help Client A today—and THAT with my deck for Client B tomorrow.” So I’m sharing it here. Free. No registration or email required.

What You Get (for free)

It’s a 44-page booklet in two parts.

The first 17 pages introduce 21 consulting skills—from framing a problem and auditing assumptions to pricing strategy, competitive war-gaming, and writing a decision memo. Each includes a reusable instruction you can paste into Claude, plus a worked example involving a fictional genomics company facing major strategic decisions.

Pages 18–44 start over and take that same company through a detailed consulting engagement. You see how the skills connect, how one finding changes the next decision, and how the analysis becomes a recommendation for the board..

It’s a little “MBA in a Box”—with a genomics startup as the classroom.

DOWNLOAD IT HERE.


----
In the case study, nearly every fact is labeled with its origin.  S, sourced from a "data room" (a list of key facts), D (derived from such facts, such as revenue - cost = profit [D]).  Or A, assumed, which you'll find why in that sentence or two. 

___
This source offers a booklet of 21 Claude Consulting Skills based on email registration and temporary access.  I'm dubious how great it is.  I bet you can do better.  Please use Fable t5.1 medium to simulate this booklet (see attached) and its 21 topics where Claude Fable can simulate real consulting teams and outputs.  The attachment is the cover page - simulate the booklet.

This was my initial prompt, with some screen shots of covers. It came back with a book, 16pp,  7500 words.  It offered to expand with a detailed business school type case study; I said yes. Claude then basically doubled its length which produced the 44 page work product.  Claude and I spent perhaps an hour with back-and-forth refinements.  

The case study, which Claude made up quickly while writing its deliverable.Meridian Genomics is a fictional 120-person CLIA lab in Phoenix with a tumor-informed MRD assay for colorectal cancer. It has a PLA code but no Medicare coverage, $14 million in revenue, a $6.2 million annual loss, and $22 million in cash. The board wants a three-year plan and has mostly decided what it should say: get MolDX coverage. Management’s plan is to submit in early 2027, expect coverage a year later at about the $1,900 rate the dominant national competitor reportedly receives, and triple commercial volume by 2029.

The first twist comes from arithmetic on the client’s own numbers. Meridian’s fully loaded cost per test is $2,100. Its commercial tests bring in $1,522, so each one loses $578. Coverage at $1,900 would still lose about $200 per test. The board’s strategy would turn a flat, money-losing channel into a growing, money-losing channel. The real business is biopharma. Trial sponsors using the assay as an endpoint account for 68% of revenue, grew 40% without any sales effort, and earn about $694 per test. The board had been treating that business as a bridge to coverage.

The second twist is in the profit pool. The money in MRD isn’t in the test fee. It sits in trial services, meaning documentation, logistics and regulatory support, and in licensing longitudinal data. Meridian already does trial services but has never charged for them as a product. The national competitor’s low-margin covered volume turns out to be a way of building the data asset.

The recommendation is to make trial services a named business line with per-program pricing, data-rights clauses and regulatory-grade documentation, and to cut cost per test toward $1,400. Meridian would prepare the coverage dossier but submit it only after passing gates the board sets: cost at or below $1,500, a full sponsor pipeline, and a realistic MolDX timeline. In the base case this is worth about +$19 million in NPV, compared with roughly −$2 million for cost-then-coverage. The downside is mild under this plan and could eat most of the balance sheet under the coverage-first plan.

The third twist comes from the war game. It breaks an earlier assumption that the competitor would take 12 to 18 months to respond. In the simulation it offers sponsors free assays in exchange for data rights within a year. Meridian can’t beat free on price, so it retreats to registrational trials, where documentation and exclusivity are worth more than a discount. That revision then flows back into the segmentation and the roadmap.


Wednesday, November 4, 2026

CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded

 

CMS Pulls Algorithmic Lab Tests Off the CLFS: The CY2027 SaMS Rules, Decoded

Wednesday, November 4, 2026

AI CORNER [New replacement article, Claude, issued Nov 9]

OPPS final rule:

https://www.federalregister.gov/documents/2026/11/06/2026-22739/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment 

PFS final rule:

https://www.federalregister.gov/documents/2026/11/09/2026-22743/medicare-and-medicaid-programs-cy-2027-payment-policies-under-the-physician-fee-schedule-and-other 

Read here or download as 12p PDF report.



_ _ _

A Big Change - Suddenly It's Here

The CY2027 OPPS and PFS final rules contain a policy that looks like housekeeping. It isn't. CMS has decided that a stand-alone algorithm run on lab data that already exists is not a clinical laboratory test at all. That covers a genome re-analysis, an AI read of a digitized H&E slide, and a classifier applied to an RNA transcriptome. Each is now an "other diagnostic test," a cousin of the AI-read CT scan, and starting January 1 it gets paid like one.

For 2027 the dollars barely move. Almost everything else does: who pays coinsurance, which date-of-service rule applies (none of the lab ones), how new codes get priced (nobody quite knows), and whether a code that includes staining a slide counts as "software" (it depends). Here's the tour.

The Short Version

CMS finalized 14 CPT codes (up from 10 proposed) that leave the Clinical Laboratory Fee Schedule. Under the OPPS they move to new technology APCs with a brand-new status indicator, O1 ("Software as a Medical Service"), which flags them as software and pays them separately. Under the PFS they get national pricing with procedure status A (active). Payment is crosswalked from 2026 CLFS rates and rounded into the fixed new technology payment bands, so the prices are familiar.

The surroundings are not. These services now carry ordinary Part B cost-sharing. They escape the laboratory 14-day date-of-service rule. And they sit inside payment systems built on budget neutrality and, perhaps eventually, packaging. CMS corrected its code list after comment (two codes out, two in, one long-deleted code dropped, two moved up a payment band), but it gave up nothing on principle. It has said where future algorithmic lab codes will be paid, but not how they will be priced when they arrive.

There is also a true philosophical oddity underneath the rulemaking for SaMS. Physical work does not disqualify a service from the SaMS category (it is almost welcomed), unless that physical work happens to be laboratory work. More on that below. 

Why Some Genomics Labs Reach Financial "Escape Velocity" - But Many Don't

Recently, Merck KGaA annnounced it was acquiring BioTechne for over $11 billion dollars.  BioTechne's management has been strong - that's up from a $5B valuation about ten years ago.  So the C-level team knew what it was doing.

But, if you look through a genomics lens, along the way the same BioTechne C-suite bought Exosome Dx for $325M (2018) and sold it  for $15M (2025).   Why was it so difficult to forecast the value of the Exosome business - by twenty-fold (5%)?

We discuss in a new white paper why the financials of the genomics industry can be so noisy, and often for reasons that will be missed by outsiders.

Our paper includs a humous appendix of real statements from genomic SEC documents.  Like, 'We may get paid rarely, if ever."

Find the white paper in the cloud HERE.